Skip to main content
SpringerLink
Log in

Erlotinib reduces AE rate and healthcare costs versus afatinib

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. epidermal growth factor receptor

  2. 2015 euros

Reference

  • Isla D, et al. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEconomics and Outcomes Research 2017: 31-38, No. 9, 30 Dec 2016. Available from: URL: https://doi.org/10.2147/CEOR.S121093

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erlotinib reduces AE rate and healthcare costs versus afatinib. Reactions Weekly 1635, 9 (2017). https://doi.org/10.1007/s40278-017-25258-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-25258-5

Search

Navigation